levofloxacinstarry

starry  时间:2021-01-09  阅读:()
RegulatoryStoryGotomarketnewssectionCompanyCathayInternationalHoldingsLdTIDMCTIHeadlineZhejiangStarryPharmaceuticalCo.
,Ltd.
Released07:0016-Nov-2010Number2440W07RNSNumber:2440WCathayInternationalHoldingsLd16November2010CATHAYINTERNATIONALHOLDINGSLIMITEDProposedminorityinvestmentinZhejiangStarryPharmaceuticalCo.
,Ltd.
('Starry')CathayInternationalHoldingsLtd.
(LSE:CTI.
L)('Cathay'orthe'Company'),acompanyinvestingprimarilyinthegrowingpharmaceuticalandhealthcaresectorsinthePeople'sRepublicofChina('PRC'),announcestodaythat:·LansenPharmaceuticalHoldingsLimited(HKE:503.
HK)('Lansen'),theCompany'ssubsidiarylistedonthemainboardoftheHongKongExchange,hasannouncedtodaythatithasagreedthetermsforthepurchaseofa20%equityinterestinStarry('Lansen'sInvestment')fromanindependentthirdpartyforacashconsiderationofapproximatelyUS$24million;and·theCompanyhasagreedthetermsforthepurchaseofa1.
5%equityinterestinStarry(the'Company'sInvestment')fromthesameindependentthirdpartyforacashconsiderationofapproximatelyUS$1.
8million.
DetailsofthetransactionLansen'sInvestmentistobeeffectedpursuanttoanequitytransferagreement(the'LansenAgreement')underwhichLansenInvestments(HongKong)Limited('LSI'),anindirectwhollyownedsubsidiaryofLansen,hasagreedtopurchaseandMr.
LiewYewThoong(the'Vendor'),oneoftheexistingminorityshareholdersofStarry,hasagreedtosell,20%oftheregisteredcapitalofStarryforacashconsiderationofapproximatelyUS$24million(RMB160million).
TheCompany'sInvestmentistobeeffectedpursuanttoaseparateequitytransferagreement(the'CathayAgreement')underwhichFullKeenLimited('FKL')anindirectwholly-ownedsubsidiaryoftheCompany,hasagreedtopurchaseandtheVendorhasagreedtosell,1.
5%oftheregisteredcapitalofStarryforacashconsiderationofapproximatelyUS$1.
8million(RMB12million).
ZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
1of411/16/20103:03PMInformationonStarryStarryisasino-foreignequityjointventureincorporatedunderthelawsofthePRC.
Itisacompanyspecializingintheproductionofbulkpharmaceuticalsandintermediates.
ThetwocorebulkpharmaceuticalproductsofStarryareiohexolforX-CTnon-ioniccontrastagentsandlevofloxacinforantibiotics.
StarryisthelargestiohexolmanufacturerinthePRCandisexperiencedintheproductionmanagementandqualitycontrolofbulkpharmaceuticals.
SetoutbelowisasummaryoftheauditedfinancialresultsofStarryforthetwoyearsended31December2008and31December2009,whichwerepreparedinaccordancewiththePRCgenerallyacceptedaccountingprinciples:Yearended31December20092008EquivalentEquivalentRMB'000US$'000RMB'000US$'000Profitbeforetaxation57,9748,72532,8604,945Profitaftertaxation57,9748,72532,8604,945Grossassets549,49182,698467,79470,403Netassets199,70730,056139,05320,927ConsiderationTheconsiderationforLansen'sInvestmentisRMB160million(approximatelyUS$24million),whichshallbefundedthroughtheexistinginternalresourcesoftheLansengroup.
TheconsiderationfortheCompany'sInvestmentisRMB12million(approximatelyUS$1.
8million).
TheconsiderationwillbesatisfiedoutoftheCompany'sinternalresources.
Theconsiderationwasagreedafterarm'slengthnegotiationsbetweenLansen,theCompanyandtheVendor,takingintoconsideration,amongstotherthings,(i)thenetassetvalueofStarryasat31December2009;(ii)futureprospectsofthebusinessofStarry;(iii)theprospectsofthepharmaceuticalindustryinthePRCasawhole;and(iv)tradingpriceearningsmultiplesofStarry'smarketcomparablesinthePRC.
TheconsiderationpayablefortheCompany'sInvestmentandLansen'sInvestmentshallbesettledwithin10businessdaysofreceiptoftherelevantgovernmentapprovalinthePRCforthetransferoftheequityinterestsundertherespectiveagreement.
Iftherelevantgovernmentapprovalforthetransferoftheequityinterestsisnotreceivedwithin60daysfromthedateoftheapplicationforapproval(orsuchotherdateastheVendorandLSIorFKL,asthecasemaybe,mayagree)theLansenAgreementandtheCathayAgreementshalllapseandbeofnofurtherforceandeffect.
EffectofthetransactionontheCathaygroupandbenefitsofthetransactionThereasonsforandexpectedbenefitsofLansen'sInvestmentincludethefollowingmatters:·OneofLansen'sstrategiesistoexploreopportunities,throughbusinessalliancesoracquisitions,whichwouldexpanditsproductrangeofrheumaticspecialtydrugs,includingtheupstreambulkpharmaceuticalproductionforrheumaticspecialtydrugs.
TheboardofLansenbelievesthatLansen'sInvestmentprovidesLansenwithopportunitiestoparticipateintheupstreamZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
2of411/16/20103:03PMsupplybusinessinthepharmaceuticalindustryvaluechain.
Lansen'sInvestmentisofstrategicsignificancesinceLansen'sInvestmentwillallowittodevelopexperienceintheproductionmanagementandcontrolofbulkpharmaceuticalsforitsdrugsinthefuture.
·Theimpactonbulkpharmaceuticalsappeartobelesssubstantialthantheimpactondownstreampharmaceuticalproductsundertherecent"DrugPriceControlMeasures"discussionpaperpublishedbythePRCgovernment.
Lansen'sInvestmentwillachieveacertaindegreeofdiversificationofproductconcentrationrisk.
·Lansen'sboardbelievesthatLansen'sInvestmentisconsistentwithLansen'sbusinessobjectiveofestablishingandstrengtheningbusinessallianceswithpharmaceuticalcompanies.
LansenwillbenefitfromStarry'sexperienceinareasincludingrawmaterialsproductiontechnology,GMPcertification,costandqualitycontrol,andenvironmentalprotection.
LansenisnotexpectedtodevotesignificanthumanandmanagementresourcestoStarry'soperations.
·Lansen'sboardconsidersthatthetermsandconditionsoftheLansenAgreement,includingtheconsiderationthereof,arefairandreasonableandthattheenteringintooftheLansenAgreementisintheinterestsofLansenanditsshareholdersasawhole.
ForCathay,theCompany'sInvestmentisinlinewiththeintentionstatedintheCompany's2010interimreporttospecializeinthefastgrowingpharmaceutical,healthcareandenvironmentprotectionmarketsandtowidentheinvestmentscopeoftheCathayGrouptoincludepotentialminorityinvestmentpositions.
TheBoardofCathayconsidersthatthetermsandconditionsoftheCathayAgreement,includingtheconsiderationthereof,arefairandreasonableandthattheenteringintooftheCathayAgreementisintheinterestsoftheCompanyanditsshareholdersasawhole.
DetailsofkeyindividualsimportanttothebusinessofStarryMr.
HuJinsheng,56,founderandoneofthemajorshareholdersofStarry,hasbeeninthebusinessforthirtyyearsandpossessesextensiveexperienceinoperationalandfinancialmanagementissues.
Mr.
HuJinshengistheGeneralManagerofStarry.
Mr.
HuJian,thesonofMr.
HuJinsheng,isanothermajorshareholderofStarry.
Mr.
HuJianistheDeputyGeneralManagerofStarry.
EnquiriesCathayInternationalHoldingsLimited+85228289289JinyiLee/EricSiuBrunswick+44(0)2074045959JonColesCertainstatementsinthisannouncementareforward-lookingstatements.
ThesestatementsrelatetotheCathayGroup'sfutureprospects,developmentsandbusinessstrategies.
Forward-lookingstatementsareidentifiedbytheiruseoftermsandphrasessuchas"believe","could","envisage","estimate","intend","may","plan","will"orthenegativeofthose,variationsorcomparableexpressions,includingreferencestoassumptions.
Theforward-lookingstatementsinthisannouncementarebasedoncurrentexpectationsandaresubjecttorisksanduncertaintiesthatcouldcauseactualresultstodiffermateriallyfromthoseexpressedorimpliedbythosestatements.
Giventheserisksanduncertainties,potentialinvestorsshouldnotplaceanyrelianceonforward-lookingZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
3of411/16/20103:03PMstatements.
Theseforward-lookingstatementsspeakonlyasatthedateofthisannouncement.
NeithertheDirectorsnortheCompanyundertakeanyobligationtoupdateforward-lookingstatementsotherthanasrequiredbytheListingRules,DisclosureandTransparencyRules,applicablelegislationorbytherulesofanyothersecuritiesregulatoryauthority,whetherasaresultofnewinformation,futureeventsorotherwise.
ThisinformationisprovidedbyRNSThecompanynewsservicefromtheLondonStockExchangeENDMSCDMMMMVVRGGZGLondonStockExchangeplcisnotresponsibleforanddoesnotcheckcontentonthisWebsite.
Websiteusersareresponsibleforcheckingcontent.
Anynewsitem(includinganyprospectus)whichisaddressedsolelytothepersonsandcountriesspecifiedthereinshouldnotberelieduponotherthanbysuchpersonsand/oroutsidethespecifiedcountries.
Termsandconditions,includingrestrictionsonuseanddistributionapply.
2009LondonStockExchangeplc.
AllrightsreservedRegulatoryZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
4of411/16/20103:03PM

易探云香港vps主机价格多少钱?香港云服务器主机租用价格

易探云香港vps主机价格多少钱?香港vps主机租用费用大体上是由配置决定的,我们选择香港vps主机租用最大的优势是免备案vps。但是,每家服务商的机房、配置、定价也不同。我们以最基础配置为标准,综合比对各大香港vps主机供应商的价格,即可选到高性能、价格适中的香港vps主机。通常1核CPU、1G内存、2Mbps独享带宽,价格在30元-120元/月。不过,易探云香港vps主机推出四个机房的优惠活动,...

HostKvm:香港国际/韩国KVM夏季7折,2G内存套餐月付5.95美元起

HostKvm是一家成立于2013年的国外主机服务商,主要提供基于KVM架构的VPS主机,可选数据中心包括日本、新加坡、韩国、美国、中国香港等多个地区机房,均为国内直连或优化线路,延迟较低,适合建站或者远程办公等。目前商家发布了夏季特别促销活动,针对香港国际/韩国机房VPS主机提供7折优惠码,其他机房全场8折,优惠后2GB内存套餐月付5.95美元起。下面分别列出几款主机套餐配置信息。套餐:韩国KR...

杭州王小玉网-美国CERA 2核8G内存19.9元/月,香港,日本E3/16G/20M CN2带宽150元/月,美国宿主机1500元,国内宿主机1200元

官方网站:点击访问王小玉网络官网活动方案:买美国云服务器就选MF.0220.CN 实力 强 强 强!!!杭州王小玉网络 旗下 魔方资源池 “我亏本你引流活动 ” mf.0220.CNCPU型号内存硬盘美国CERA机房 E5 2696v2 2核心8G30G总硬盘1个独立IP19.9元/月 续费同价mf.0220.CN 购买湖北100G防御 E5 2690v2 4核心4G...

starry为你推荐
海外虚拟主机请推荐下国外的虚拟主机?国内域名注册国内比较出名的域名注册商有哪些?海外虚拟主机空间建个网站、买一个国外的空间或是虚拟主机、请问哪里有?海外服务器租用国外服务器租用与国内服务器租用有哪些区别已备案域名查询如何查询网站的域名是否已经备案已备案域名查询已经有个顶级域名,怎么查询是否备案?国外空间租用租用美国空间vps试用请问有什么网站可以提供免费vps试用的?想用它来刷一下外国pt站国内免费空间免费空间哪个好用虚拟主机申请在哪里可以申请到虚拟主机呢
申请域名 com域名注册1元 vps服务器租用 域名备案流程 2019年感恩节 电信测速器 68.168.16.150 国内加速器 169邮箱 linux服务器维护 免费申请网站 如何用qq邮箱发邮件 电信虚拟主机 银盘服务 360云服务 海外空间 沈阳主机托管 starry 东莞主机托管 iki 更多